Medical Lab Report Analysis - Omkar Nishad, 17 yr/M

Disclaimer: This is an educational analysis to help understand the reports. It is NOT a substitute for evaluation by a qualified physician. The reports themselves advise clinical correlation.

Report 1: Urine Routine & Microscopy - Key Findings

• Hematuria (blood in urine) - confirmed by both dipstick (+++) and microscopy (10-20 RBCs/HPF). This is significant hematuria.
• Bilirubinuria - bilirubin in urine is always abnormal and indicates either liver cell damage (hepatocellular disease) or bile duct obstruction. However, urobilinogen is normal, which suggests the bilirubin reaching the urine is conjugated (direct) bilirubin - pointing toward hepatocellular or cholestatic disease.
• No evidence of urinary tract infection (nitrite negative, leucocyte esterase negative, bacteria absent).

Report 2: USG Whole Abdomen - Key Findings

Synthesis & Differential Diagnosis

1. Splenomegaly
2. Minimal ascites
3. Bowel inflammation / increased bowel motility
4. Bilirubinuria (conjugated bilirubin leaking into urine)
5. Significant hematuria (10-20 RBCs/HPF)
6. GB sludge

Most Likely Diagnosis: Enteric Fever (Typhoid Fever)

• Splenomegaly is a classic and well-documented feature of typhoid fever, occurring in the majority of hospitalized cases. Per Harrison's Principles of Internal Medicine and the AAP Red Book: "Enteric fever is a syndrome characterized by fever, headache, abdominal pain, splenomegaly, and leukopenia."
• Bowel inflammation with increased peristalsis matches the intestinal phase of typhoid (Peyer patch involvement).
• GB sludge is consistent with Salmonella tropism for the gallbladder (S. Typhi colonizes the biliary system).
• Bilirubinuria can occur in typhoid due to mild hepatitis (typhoid hepatitis), causing conjugated bilirubin to spill into urine.
• Minimal ascites can accompany typhoid fever, particularly with enteric involvement.
• Hematuria, though less common, is a recognized complication - GI bleeding occurs in ~10% of hospitalized typhoid patients, and urinary involvement has been reported.

Secondary/Alternative Differentials to Exclude:

What Tests Should Be Done Next

1. Typhidot / Widal Test - rapid serology for Salmonella Typhi antibodies
2. Blood Culture - gold standard for typhoid (positive in ~60-80% in first week)
3. Complete Blood Count (CBC) - look for leukopenia (low WBC), relative lymphocytosis, thrombocytopenia (classic in typhoid)
4. Liver Function Tests (LFTs) - confirm/quantify hepatic involvement, measure direct vs. indirect bilirubin
5. Peripheral Blood Smear + Malaria RDT/PCR - to rule out malaria
6. Stool Culture - supportive evidence for enteric fever
7. Dengue NS1/IgM - Gorakhpur has high dengue burden; can cause thrombocytopenia + splenomegaly

Summary

Working Diagnosis: Enteric Fever (Typhoid/Paratyphoid Fever) with hepatic involvement

Histopathology Report Analysis - Mithu Devi, 40 yr / Female

Important Notice: This is a confirmed malignancy (cancer). The histopathology report has been issued and signed by two qualified MD Pathologists. The patient must be referred urgently to a gynecologic oncologist for staging and treatment planning without delay.

Patient & Specimen Details

What the Report Found

Specimen A - Cervical Biopsy (Microscopic Findings)

• Sheets of malignant squamous epithelial cells diffusely invading the cervical stroma
• Cells are moderately differentiated with moderate anisocytosis (variation in cell size) and anisonucleosis (variation in nuclear size)
• Hyperchromasia (dark-staining nuclei) with opened chromatin and prominent nucleoli - hallmark features of malignant cells
• Mixed cytoplasm: some cells clear, some eosinophilic (indicating squamous lineage)
• Stroma infiltrated by chronic inflammatory cells

Specimen B - Endometrial Biopsy (Microscopic Findings)

• No normal endometrial tissue is seen
• The section shows infiltration by the same tumor described in specimen A
• This means the cervical cancer has extended into the uterine cavity/endometrium

Pathologist's Final Opinion (as stated in report)

Clinical Interpretation

Diagnosis: Invasive Squamous Cell Carcinoma of the Cervix with Uterine/Endometrial Extension

• Large polygonal cells forming sheets and nests
• No keratin pearl formation (unlike well-differentiated keratinizing type)
• Greater nuclear pleomorphism - more aggressive than well-differentiated but better than small cell type

Urgent Next Steps Required

1. MRI Pelvis with contrast - to assess: parametrial invasion, depth of stromal invasion, vaginal involvement, lymph node status. MRI is the gold standard for local staging of cervical cancer.
2. CT Chest/Abdomen/Pelvis (or PET-CT) - to detect distant lymph node metastases (iliac, para-aortic) and distant spread (lungs, liver, bones).
3. Complete gynecologic examination under anesthesia (EUA) - clinical staging by gynecologic oncologist.
4. HPV genotyping - not mandatory for treatment but prognostically informative.
5. Hemoglobin / CBC / Renal function tests - pre-treatment baseline, especially important before radiation therapy (anemia worsens radiation response).
6. Urgent referral to Gynecologic Oncology - treatment options include surgery (radical hysterectomy for early stage) or chemoradiation (cisplatin-based concurrent chemoradiotherapy is standard for locally advanced disease).

5-Year Survival Reference (by FIGO Stage)

Summary

Diagnosis: Invasive Squamous Cell Carcinoma of the Cervix (Moderately Differentiated, Large Cell Non-Keratinizing), with Extension to Endometrium

Treatment Plan: Cervical Squamous Cell Carcinoma with Uterine Extension

Patient: Mithu Devi, 40 yrs / Female

Note: Treatment must be planned by a gynecologic oncologist after formal FIGO staging via MRI and CT/PET-CT. This guide presents the evidence-based framework from current international guidelines (FIGO 2018, ESGO 2023, NCCN, Berek & Novak's Gynecology).

Step 1: Staging First (Determines Everything)

Stage-Based Treatment Algorithm

If Stage IIA (cervix + upper vagina, no parametrial involvement)

• Type III Radical Hysterectomy (Wertheim's hysterectomy) + bilateral pelvic lymph node dissection
• Removes: uterus, cervix, upper 1/3 vagina, parametrium, pelvic lymph nodes
• At age 40, ovaries can be preserved (squamous cell carcinoma rarely spreads to ovaries - <1% risk)
• If post-operative pathology shows high-risk features (positive nodes, positive margins, parametrial invasion) → add adjuvant chemoradiation
• 4-year survival with adjuvant chemoradiation after surgery: ~81% (GOG intergroup trial)

• Used if tumor >4 cm, patient unfit for surgery, or if surgery would require adjuvant radiation anyway (avoids dual-modality morbidity)

If Stage IIB or III (parametrial invasion / pelvic wall involvement) - Likely in this case

Standard Treatment: Concurrent Chemoradiation (CCRT) + Brachytherapy

• Whole pelvis radiation: 45-50 Gy delivered in 25-28 fractions over 5 weeks
• Covers the cervix, uterus, parametrium, regional lymph nodes
• Must be completed within 8 weeks total

• Cisplatin 40 mg/m² IV weekly during radiation (5-6 cycles)
• Cisplatin sensitizes cancer cells to radiation, improving local control and survival
• Survival benefit over radiation alone: 10-15% at 5 years (meta-analysis of 18 RCTs)
• Per Berek & Novak's Gynecology: "Cisplatin-based concurrent chemoradiation was a superior treatment" - established by GOG protocols 85, 120

• After EBRT, high-dose rate (HDR) intracavitary brachytherapy is given
• Delivers high-dose radiation directly to the cervix/uterus
• 3-5 fractions of 6-7 Gy each
• This is what achieves local tumor control - EBRT alone is insufficient
• Total treatment must be completed within 8 weeks (longer duration = worse outcomes)

2024-2025 Update: Immunotherapy Addition (Pembrolizumab)

• Adding pembrolizumab (Keytruda) to standard CCRT for high-risk locally advanced cervical cancer (Stage IIB+ with nodes, or Stage III-IVA) showed:
  • Improved progression-free survival (HR 0.70, p=0.002)
  • 24-month overall survival: 87% vs 81% over CCRT alone
• FDA approved pembrolizumab + CCRT for FIGO Stage III-IVA cervical cancer in January 2024
• This combination is now considered the emerging standard of care for advanced disease

Full Treatment Timeline (Typical Course)

Week 1-6:   External Beam Radiotherapy (45-50 Gy / 25 fractions)
             + Weekly Cisplatin (40 mg/m² IV) × 5-6 doses
             [+ Pembrolizumab if Stage IIB+ and available]

Week 7-8:   Brachytherapy (HDR) × 3-5 sessions
             [Total treatment ≤ 8 weeks]

After CCRT: Follow-up every 3 months × 2 years, then 6-monthly
             MRI pelvis at 3 months post-treatment to assess response

Managing Side Effects

Prognosis with Treatment

What to Do Right Now

1. Go to a Cancer Centre / Gynecologic Oncology department immediately - ideally a government cancer hospital (RIMS Lucknow, BHU Varanasi, SGPGI Lucknow, Tata Memorial Mumbai) which offers subsidized/free treatment under Ayushman Bharat (PMJAY) scheme
2. Take this histopathology report along with the slides and tissue blocks (the report says "enclosed slides & blocks for second opinion if required")
3. Get an MRI pelvis with contrast before the first oncology appointment
4. Do not delay - this tumor is already beyond the cervix; every week matters

PET-CT Report Analysis & Complete Diagnosis

Patient: Ms. Mithu Devi | Age: 48 yrs 6 months | Female | Date: 20-Jul-2026

This is a continuation of the previously analysed histopathology report (squamous cell carcinoma cervix). The PET-CT was done for pre-treatment staging - the right investigation at the right time.

Complete PET-CT Findings - Region by Region

Definitive Diagnosis

Invasive Squamous Cell Carcinoma of the Uterine Cervix

FIGO 2018 Stage IIIC1 (pIIIC1)

• Stage IIIC = Regional lymph node involvement
• IIIC1 = Pelvic lymph node metastasis (left external iliac node, confirmed on PET-CT)
• IIIC2 = Para-aortic nodes (not involved here)

Summary at a glance:

• Primary tumor: 2.8 x 4.2 x 3.4 cm, cervix + upper vagina, SUVmax 13.3 (highly metabolically active)
• Regional spread: Left external iliac lymph node metastasis (1.5 x 1.0 cm, SUVmax 14.3)
• No distant metastasis (lungs, liver, bones clear)
• No bladder or rectal invasion (very important - still Stage IIIC, not Stage IV)

Treatment Plan (2025-2026 Standard of Care)

STANDARD TREATMENT: Concurrent Chemoradiotherapy (CCRT) + Brachytherapy + Pembrolizumab

Phase 1: INDUCTION CHEMOTHERAPY (Weeks 1-6, optional but recommended)

• Carboplatin (AUC 2) + Paclitaxel (80 mg/m²) IV weekly × 6 cycles
• This "debulks" the tumor and the positive lymph node before radiation begins
• NCCN (Version 2, 2026) and ESGO guidelines both support this step

Phase 2: CONCURRENT CHEMORADIATION (CCRT) - Weeks 7-12 (5-6 weeks)

• Dose: 45-50 Gy in 25 fractions over 5 weeks (5 days/week)
• Boost to left external iliac node: Additional simultaneous integrated boost (SIB) of ~57.5 Gy to the involved lymph node
• Technique: IMRT (Intensity Modulated Radiation Therapy) or VMAT - reduces bowel and bladder toxicity
• Field: Whole pelvis covering cervix, uterus, parametrium, upper vagina, bilateral iliac, obturator, and presacral lymph nodes

• Cisplatin 40 mg/m² IV weekly × 5-6 doses during radiation
• Must pre-hydrate adequately (1-2L IV fluids) to protect kidneys
• Weekly CBC to monitor bone marrow

• Pembrolizumab 200 mg IV every 3 weeks concurrent with CCRT
• Based on KEYNOTE-A18 trial - this is now the standard for FIGO Stage III-IVA disease
• At 2-year follow-up (SGO 2025): OS 87% vs 81% (pembrolizumab vs placebo with CCRT), PFS HR 0.70
• Approved by FDA (Jan 2024), European Commission (Oct 2024), supported by NCCN 2026 and ESGO

Phase 3: BRACHYTHERAPY (After EBRT is complete)

• High-Dose Rate (HDR) Intracavitary Brachytherapy - 3-5 sessions
• Typically 6-7 Gy per fraction × 4-5 fractions
• Delivers concentrated radiation directly to the cervix/vaginal vault
• This step is non-negotiable - EBRT alone is not sufficient for local control
• Total treatment must be completed within 8 weeks of starting CCRT

Phase 4: MAINTENANCE PEMBROLIZUMAB (After CCRT completion)

• Pembrolizumab 400 mg IV every 6 weeks (or 200 mg every 3 weeks) for up to 14 additional cycles (~1 year)
• This consolidation phase is what drives the sustained survival benefit seen in KEYNOTE-A18

Treatment Timeline at a Glance

Weeks 1-6:    INDUCTION - Carboplatin + Paclitaxel weekly × 6
─────────────────────────────────────────────
Weeks 7-12:   EBRT (45-50 Gy / 25 fx) + Cisplatin (40 mg/m² weekly)
               + Pembrolizumab 200 mg every 3 weeks (concurrent)
               [Boost 57.5 Gy to left external iliac node]
─────────────────────────────────────────────
Weeks 13-15:  HDR Brachytherapy × 4-5 fractions
─────────────────────────────────────────────
Weeks 16-72:  Maintenance Pembrolizumab (14 cycles, ~1 year)
─────────────────────────────────────────────
Response assessment MRI Pelvis: 3 months after completing CCRT
PET-CT reassessment: 3-6 months post-treatment

Important Pre-Treatment Workup

Managing Key Side Effects

Prognosis

1. Only one pelvic lymph node is involved (the left external iliac)
2. No para-aortic nodes involved
3. No distant metastasis anywhere in the body
4. Bladder and rectum are not invaded
5. Both kidneys and ureters are normal

Where to Go for Treatment

• AIIMS New Delhi - Department of Radiation Oncology
• Tata Memorial Hospital, Mumbai - Premium cancer centre in India
• SGPGI, Lucknow - Closest major centre (given Gorakhpur location)
• BHU Institute of Medical Sciences, Varanasi - Regional cancer centre
• RIMS / NCI, Jhajjar (AIIMS affiliate)

Bottom line: Mithu Devi has Stage IIIC1 cervical squamous cell carcinoma - locally advanced but with no distant spread, making it potentially curable with current standards. The treatment is Concurrent Chemoradiation (cisplatin + EBRT + brachytherapy) plus Pembrolizumab immunotherapy, which is the FDA and ESGO-approved standard as of 2024-2026. Timely initiation of treatment is critical - ideally within 2-4 weeks.

Lab Report Analysis - Mrs. Shanti Devi

Age: 50 years | Female | Date: 21-Jul-2026 | Lab: Doctors Diagnostic

Disclaimer: This analysis is for educational purposes. All findings must be evaluated and managed by a qualified physician.

Complete Lab Values at a Glance

Diagnosis

Primary Diagnosis: PREDIABETES

• Fasting glucose: 124.2 mg/dL
• The ADA threshold for diabetes is ≥126 mg/dL - she is 1.8 mg/dL below the diabetic cutoff
• IFG range is 100-125 mg/dL - she is at the very top

• 2-hour postprandial glucose: 172.2 mg/dL
• Normal is <140; diabetic is ≥200 - she falls in the prediabetes zone (140-199)

• ADA defines prediabetes as HbA1c 5.7-6.4%
• Her HbA1c of 5.9% confirms prediabetes (average blood sugar over the past 3 months has been elevated)
• Below 6% prediabetes range by some labs, but ADA 5.7-6.4% range makes 5.9% clearly prediabetic

Critical Note: Having both IFG and IGT together (rather than one alone) carries a significantly higher risk of progression to Type 2 Diabetes - studies show ~65% risk of progressing to T2DM within 6 years without intervention. This patient needs immediate lifestyle intervention.

Secondary Finding: Borderline Dyslipidaemia

• Triglycerides: 169.2 mg/dL - borderline high (normal <150 mg/dL by ATP III guidelines; lab's reference goes to 200, but clinical risk starts above 150)
• VLDL: 34 mg/dL - slightly elevated (VLDL is elevated because it carries triglycerides)
• HDL: 62.3 mg/dL - slightly above the lab's reference, but this is actually favorable - high HDL is cardioprotective

Secondary Finding: Serum Uric Acid at Upper Limit

• Uric acid: 6.4 mg/dL - exactly at the upper limit for females (2.0-6.4)
• Hyperuricemia in women is associated with insulin resistance and metabolic syndrome
• She should avoid high-purine foods (red meat, organ meats, shellfish) and limit fructose/sugary drinks
• No action needed unless symptomatic (joint pain/gout), but monitor

Normal Findings

• Kidney function: NORMAL (urea 26.9, creatinine 0.97) - good, no diabetic nephropathy at this stage
• TSH: NORMAL (3.07) - thyroid is functioning well; hypothyroidism as a cause of dyslipidaemia ruled out
• Total cholesterol: NORMAL (180.9)
• LDL: NORMAL (85) - well below risk threshold
• Cardiovascular risk ratios: LOW (Chol/HDL 2.9, LDL/HDL 1.36 - both excellent)

Diagnosis Summary

Metabolic Syndrome / Prediabetes with Borderline Hypertriglyceridaemia

• Impaired Fasting Glucose (124.2 mg/dL)
• Impaired Glucose Tolerance (PP 172.2 mg/dL)
• HbA1c 5.9% (Prediabetes range)
• Borderline hypertriglyceridaemia (169.2 mg/dL) + elevated VLDL
• Uric acid at upper limit of normal

Treatment Plan

STEP 1: LIFESTYLE MODIFICATION (First and Most Important Intervention)

• Reduce simple carbohydrates: No white rice in large portions, no sugar, no refined flour (maida). Replace with whole grains - roti (small), brown rice, oats, millets (bajra, jowar, ragi)
• Low glycaemic index foods: Dal, vegetables, legumes (rajma, chana), salads
• Reduce saturated fat to help triglycerides: Less ghee/butter, no fried foods, minimal full-fat dairy
• For triglycerides specifically: Avoid sugary drinks (cold drinks, packaged juice), limit fruit juice, reduce alcohol if consuming any
• Increase dietary fibre: 25-30 g/day - vegetables, fruits with skin, whole grains
• Portion control: Smaller, more frequent meals (5-6 small meals) rather than 2-3 large meals
• Best dietary patterns (ADA 2025): Mediterranean diet or DASH diet are strongly recommended

• Target: 150 minutes per week of moderate-intensity aerobic exercise
• Practical: 30 minutes of brisk walking, 5 days a week
• Add resistance training (bodyweight exercises, yoga) 2 days per week - ADA 2025 now specifically highlights resistance training
• Physical activity is one of the most powerful tools to reduce fasting glucose and HbA1c

• If overweight (BMI >23 in Asian women), 5-7% weight loss can reduce diabetes risk by 58% (Diabetes Prevention Program)
• Target: Prevent weight gain; aim for gradual loss

• ADA 2025 now specifically identifies sleep as equally important as diet and exercise
• Target: 7-8 hours of quality sleep per night
• Poor sleep worsens insulin resistance significantly

STEP 2: PHARMACOLOGICAL TREATMENT

• Metformin 500 mg once daily with dinner (or twice daily after meals)
• Evidence: Reduces T2DM progression by ~31% in prediabetes
• ADA 2025: Recommended for prediabetes if BMI ≥35, HbA1c >6%, age <60, or history of gestational diabetes
• Very safe, cheap, widely available
• Side effects: Nausea, diarrhea initially (take with food); rare B12 deficiency with long-term use

• E.g., Semaglutide (Ozempic/Rybelsus) - effective for weight loss, glucose reduction, and triglyceride reduction
• Especially relevant if patient is overweight
• More expensive; discuss with physician

Note: Whether to start medication or try lifestyle changes first for 3 months is a decision for her treating physician based on clinical examination.

STEP 3: MANAGING BORDERLINE TRIGLYCERIDES

• Primary approach: Diet and exercise (as above - reducing refined carbs and sugars is the most effective way to lower triglycerides)
• Omega-3 fatty acids: Fish oil 1-2g/day OR flaxseeds/walnuts daily - reduces triglycerides
• If triglycerides remain >200 after 3 months of lifestyle change: Consider Fenofibrate 145 mg once daily (discuss with physician)
• Her LDL is excellent (85) and HDL is actually good, so statin therapy is NOT needed at this time

STEP 4: MONITORING SCHEDULE

STEP 5: SPECIALIST REFERRAL

• Diabetologist / Endocrinologist - for formal prediabetes management, decision on Metformin
• Dietitian - for personalized meal planning
• Consider Diabetes Prevention Program (DPP) - structured 12-16 week lifestyle intervention program (if available locally)

Key Message for the Patient

Mrs. Shanti Devi's blood reports show prediabetes - she does not have full diabetes yet, but is on the borderline. This is the most important time to act. With proper diet, daily walking, and weight management, she has a very good chance of returning to normal blood sugar levels and never developing Type 2 Diabetes. Her kidney function, thyroid, and heart risk markers (cholesterol ratios) are all reassuring. The triglycerides are mildly elevated but manageable with diet changes. She should follow up with her doctor in 3 months with repeat FBS, PPBS, and HbA1c to track progress.

Apollo Hospital Report Analysis - Mrs. Mithu Devi

Female | Age: 48Y 6M | DOB: 01-Jan-1978 | Visit Date: 27-Jul-2026

Doctor: Dr. Aditi Aggarwal, Senior Consultant - Radiation Oncology, Indraprastha Apollo Hospitals, New Delhi

This is the same patient whose histopathology (July 9) and PET-CT (July 20) reports were previously analysed. This Apollo Hospitals visit represents her formal oncology consultation at a tertiary cancer centre, confirming the diagnosis and initiating a treatment plan.

Complete Clinical Summary - What the Reports Say

Timeline of Investigations Done So Far:

Physical Examination Findings (18.07.2026):

• Bulky growth involving anterior lip of cervix ~5 x 4 cm (larger on clinical exam than imaging)
• Vagina: free
• Bilateral parametria: supple (not indurated - good sign)
• Bilateral fornices: free
• Rectal mucosa: free
• No palpable lymph nodes on examination

Official Diagnosis (as written by Apollo Radiation Oncologist):

Ca Cervix (SCC) - T2aN1M0, FIGO IIIC1, PDL1-TPS-10

Why PDL1-TPS 10 is Important:

• PD-L1 TPS (Tumour Proportion Score) measures what percentage of tumour cells stain positive for PD-L1 protein
• A TPS ≥ 1% qualifies for pembrolizumab
• This patient's TPS of 10% confirms she is fully eligible for pembrolizumab (immunotherapy)
• KEYNOTE-A18 trial (which led to FDA approval in Jan 2024) enrolled patients with PD-L1 positive tumours - her score qualifies

Apollo's Second-Opinion Pathology - Key Addition:

Critical Concern: Worsening Anaemia

• Radiation therapy is significantly less effective when Hb < 10 g/dL (hypoxic tumour cells are radioresistant)
• Chemo/radiation cannot safely start with Hb 6.7 - the anaemia must be corrected first
• Chemotherapy (cisplatin) requires adequate blood counts

Complete Treatment Plan

IMMEDIATE PRIORITY: Correct Anaemia Before Starting CCRT

1. Blood Transfusion - Packed Red Cell Transfusion (PRBC) to raise Hb to ≥10 g/dL before starting treatment. Likely 2-3 units needed.
2. IV Iron (Ferric Carboxymaltose or Iron Sucrose) - if iron deficiency component; faster than oral iron
3. Erythropoiesis-Stimulating Agents - if chronic anaemia component
4. Haemostasis - the ongoing bleeding must be controlled; Apollo may place a vaginal pack, or consider short-course palliative radiotherapy to stop bleeding before definitive treatment starts

Target Hb before starting chemoradiation: ≥ 10 g/dL (ideally ≥ 12 g/dL)

DEFINITIVE TREATMENT PROTOCOL: CCRT + Pembrolizumab (2026 Standard of Care)

Phase 1: CONCURRENT CHEMORADIATION (CCRT) - 5-6 weeks

• Dose: 45-50 Gy to the whole pelvis in 25 fractions (5 days/week)
• Simultaneous Integrated Boost (SIB): Additional boost ~57.5 Gy to the left external iliac lymph node (positive on PET-CT, SUVmax 14.3)
• Technique: IMRT/VMAT (Apollo is equipped with this)
• Field: Covers entire pelvis - cervix, uterus, parametria, upper vagina, bilateral iliac and presacral nodal chains

• Cisplatin 40 mg/m² IV weekly × 5-6 doses during EBRT
• Mandatory pre-hydration with 1-2L IV fluids to protect kidneys (her KFT was normal - good baseline)
• Weekly CBC to monitor; hold if WBC <3000 or platelets <75,000

• Pembrolizumab 200 mg IV every 3 weeks concurrently with CCRT
• Approved by FDA (Jan 2024), ESMO-MCBS Grade A evidence (KEYNOTE-A18)
• Her PDL1-TPS of 10% confirms eligibility
• NCCN 2026 Guidelines: Category 1 recommendation for FIGO 2014 Stage III-IVA

Phase 2: BRACHYTHERAPY (After EBRT completion)

• HDR Intracavitary Brachytherapy × 4-5 fractions (6-7 Gy per fraction)
• Delivered directly to the cervix using an intrauterine applicator
• Non-negotiable component - essential for local tumour control
• Total treatment (EBRT + brachy) to be completed within 8 weeks of starting

Phase 3: MAINTENANCE PEMBROLIZUMAB (After CCRT)

• Pembrolizumab 400 mg IV every 6 weeks (or 200 mg every 3 weeks) for up to 14 additional cycles (~1 year)
• This is the maintenance/consolidation phase that drives sustained survival benefit

Full Treatment Timeline

URGENT NOW:    Blood transfusion → Hb > 10 g/dL
               Block ongoing PV bleeding

Weeks 1-6:     EBRT (45-50 Gy / 25 fx + SIB to LN)
               + Cisplatin 40 mg/m² weekly × 5-6
               + Pembrolizumab 200 mg every 3 weeks (concurrent)

Weeks 7-8:     HDR Brachytherapy × 4-5 sessions
               [Total CCRT must be ≤ 8 weeks]

Weeks 9-60:    Maintenance Pembrolizumab × 14 cycles (~1 year)

Follow-up:     MRI Pelvis at 3 months post-treatment
               PET-CT at 3-6 months post-treatment
               CBC/LFT/KFT every cycle

Side Effect Management (Specific to This Patient)

Prognosis

Summary for the Family

Mrs. Mithu Devi has Stage IIIC1 cervical cancer (SCC) - confirmed by the top cancer specialists at Apollo Hospitals, New Delhi. The cancer involves the cervix and has spread to one pelvic lymph node. There is no spread to the lungs, liver, bones, or distant organs - this is the most important good news. She is now at the right centre for treatment. The treatment will be a combination of radiation therapy + cisplatin chemotherapy + pembrolizumab immunotherapy, which is the most advanced treatment available worldwide and was approved by the US FDA in 2024. Her haemoglobin is critically low (6.7) due to ongoing bleeding and must be raised with blood transfusion before treatment can start. The treating team at Apollo Radiation Oncology under Dr. Aditi Aggarwal is aware and will manage this as part of the treatment plan.